Dermavant Report Results of Tapinarof Cream in P-III PSOARING 3 Study with Durable and Remittive Benefits for Plaque Psoriasis

 Dermavant Report Results of Tapinarof Cream in P-III PSOARING 3 Study with Durable and Remittive Benefits for Plaque Psoriasis

Dermavant Report Results of Tapinarof Cream in P-III PSOARING 3 Study with Durable and Remittive Benefits for Plaque Psoriasis

Shots:

  • The P-III PSOARING 3 is an OLE study assessing Tapinarof (1%) in patients with plaque psoriasis for ~40wks. and a 4wks. safety follow-up period
  • The interim analyses showed 57.3% of study participants who entered the study with a PGA of ≥ 2 achieved a PGA of 0 or 1 while 39.2% achieved PGA 0 and the results were consistent with the previous studies. The findings will be included in NDA submission expected in mid-2021 and completion of PSOARING 3 study in H1’21
  • In an integrated analysis, 63.5% & 44.2% of subjects achieved PASI7 & 90 with the improvement in treatment effect beyond 12wks. Remittive effect of ~4mos. following treatment, discontinuation was observed

Click here ­to­ read full press release/ article | Ref: Dermavant | Image: Business Wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post